Real Chemistry, a leading provider of AI-driven insights and marketing and communications for the healthcare industry, is partnering with WhizAI, a generative AI-powered analytics platform purpose-built for life sciences and healthcare, to develop a patient journey visualization and analytics solution. This new platform promises to make it easier for clients to access accurate, contextual insights by asking conversational questions while also having the ability to visualize the process patients go through from diagnosis to treatment. The companies plan to have an initial prototype available for customers by the end of August with a more systematic rollout by the end of September.
“The work we do at IPM.ai is centered on how do we best understand the unique and differentiated journey that each patient takes as they’re seeking the appropriate diagnosis and treatment for their given condition,” Dan Fisher, Practice Leader for IPM.ai, part of Real Chemistry, told PM360. “So when we began our partnership with WhizAI, we felt that it was important to root our very precise and analytics-driven approach with the next generation of platform hosting and visualization, which WhizAI is able to bring to the table. Ultimately, we feel having our two organizations and their complementary AI and ML solutions could create an additive value for customers in the marketplace.”
As an example, Fisher says to consider the arduous and difficult journey that an oncology patient may have. Within the platform, users will be able to see how a patient’s journey will differ depending on the line of therapy they’re on, what regimens they have been exposed to in the past, or even whether there is a difference between a patient who is on Medicaid compared to a commercial plan. What makes the platform different from other patient journey offerings, according to Fisher, is that users will be able to generate a side-by-side view to compare the differential journeys that a patient may have depending on factors like those and to identify meaningful insights more quickly.
“Let’s say the time to treatment is two months faster for the patient who’s on a specific commercial plan rather than a Medicaid plan, those two months when working in critical disease states like cancer can be an eternity,” Fisher explains. “It could result in finding the right targeted therapy and intervening in time to have better outcomes for the patient. So having this insight-based platform to view those data points and to get meaningful information could have real-world impact on those patients’ lives.”
At the outset, the platform will pull from open-source claims data that Real Chemistry has access to, which provides a longitudinal view of a patient over the last 15 years for over 300 million patients in the U.S. Additionally, they will use the WhizAI platform to better understand the affiliations of how providers map across the healthcare ecosystem as well as to link payer, patient, and provider data. Further down the developmental roadmap of the platform, the companies will be working to enable clients to bridge in any purchased datasets they may have, including first-party data like lab, EHR, and registry data.
“This platform will be able to scale those large volumes of data and give a 360-degree view of a patient to any user without needing to know anything about coding or the technology on the backend,” Bijal Karande, Vice President, Partnerships, WhizAI, told PM360. “It is an easy-to-use conversational platform that allows users to ask questions in their natural language because the model is pre-trained for those types of questions. It is also specifically trained within the life sciences domain and on the type of data we are using (claims, EHR, etc.). To ensure accuracy, we are also continuously monitoring and enhancing the questions and the responses we feed back to end users.”
While patient journey mapping is not a new concept, when done correctly it can efficiently identify pain points, discover opportunities, and re-align treatment and care approaches across the healthcare ecosystem. Real Chemistry and WhizAI hope that this new platform is not only easier for users to manipulate the data to find important insights, but that it also utilizes a better approach to developing patient journey maps.
“One of the pitfalls we see with other analytics vendors working with patient journey maps is they essentially treat every patient life the exact same way,” Fisher explains. “But there is no one monolithic way that we can think about a patient’s journey. Furthermore, we know that the data we’re all working with in healthcare isn’t going to be the cleanest dataset. There’s always going to be gaps, whether it’s due to insurance coverage, the place of service for a patient, or something else. So, it is important to take an agile and flexible approach that constantly works to ensure data integrity and refines the way that we think about the patient cohort or else the end user is going to be underwhelmed with the quality of outputs that come back.”
Beyond the development of this platform, the companies hope to extend their partnership to other areas. For example, Fisher says one of the marque services at IPM.ai is providing real-time alerts or triggers to clients to better promote their products to eligible patient populations. But the company would like to take advantage of WhizAI’s platform to assess the success of these alert programs not only at a national level, but even at a territory level.
“We want to measure: How are reps interacting with the alerts they’re receiving? What do we see for performance based on different types of alerts that are being provided? How does this feed into a marketing mix analysis to show the promotional effectiveness of a given campaign?” Fisher explains. “We think this is the next frontier for how our clients—who by and large are adopting these alerts-based programs—can better interact with the data and then prove out success within their organization.”
Andrew Matthius, PM360's Senior Editor.
People also viewed
A New Era of Personalization: Applying Generative AI to Dynamic Customer Engagement
Webinar Series: Part 4 - Give Your Life Sciences Analytics the ExplAIn Advantage
Adding Up Data Analytics Total Cost of Ownership (TCO) and How to Lower It
High data analytics expenditures don’t have to be a cost of doing business for life sciences companies. WhizAI lowers the total cost of ownership (TCO) while making data insights more accessible to business users. Traditionally, data analytics TCO has been a significant expense for life sciences organizations.
Transforming Life Sciences Commercial Function with AI and Augmented Analytics
In this whitepaper, sponsored by WhizAl, Everest Group explores the business case and profound impact Al and Augmented Analytics can have on the life sciences commercial function across various use cases in Sales, Marketing, and Market Access. They examine what top pharma enterprises are looking for in an augmented analytics tool, a roadmap for how to get started, and a blueprint for adoption.
Augmented Analytics is “On the Rise” on Gartner’s 2022 Hype Cycle for Life Science Commercial Operations
The Gartner® 2022 Hype Cycle™ for Life Science Commercial Operations introduces a new category, Augmented Analytics, this year. WhizAI is listed as a sample vendor in the Augmented Analytics category in this Hype Cycle. This summary report covers the following highlights.
Why Domain Expertise Is Essential for Life Science Analytics
Domain expertise matters. Consider this: Enterprises choose transportation and logistics companies that have created the specific types of services they need. Businesses seek professional services with experience in their industries and look for consultants with good track records in their markets. However, remember that domain expertise benefits extend to analytics platforms, particularly those deployed for life sciences.